Brecht JG - Search Results

1

[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E. Schädlich PK, et al. Among authors: brecht jg. Z Rheumatol. 2004 Feb;63(1):59-75. doi: 10.1007/s00393-004-0570-y. Z Rheumatol. 2004. PMID: 14991279 German.

2

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E. Schädlich PK, et al. Among authors: brecht jg. Pharmacoeconomics. 2005;23(4):377-93. doi: 10.2165/00019053-200523040-00007. Pharmacoeconomics. 2005. PMID: 15853437

3

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E. Schädlich PK, et al. Among authors: brecht jg. Pharmacoeconomics. 2005;23(4):395-420. doi: 10.2165/00019053-200523040-00008. Pharmacoeconomics. 2005. PMID: 15853438

4

Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.

Schädlich PK, Brecht JG, Rangoonwala B, Huppertz E. Schädlich PK, et al. Among authors: brecht jg. Pharmacoeconomics. 2004;22(15):955-73. doi: 10.2165/00019053-200422150-00001. Pharmacoeconomics. 2004. PMID: 15449961

5

Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

Schädlich PK, Kentsch M, Weber M, Kämmerer W, Brecht JG, Nadipelli V, Huppertz E. Schädlich PK, et al. Among authors: brecht jg. Pharmacoeconomics. 2006;24(6):571-91. doi: 10.2165/00019053-200624060-00005. Pharmacoeconomics. 2006. PMID: 16761905

6

The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.

Schädlich PK, Brecht JG. Schädlich PK, et al. Among authors: brecht jg. Pharmacoeconomics. 1998 Jun;13(6):719-30. doi: 10.2165/00019053-199813060-00008. Pharmacoeconomics. 1998. PMID: 10179707

7

Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.

Schädlich PK, Huppertz E, Brecht JG. Schädlich PK, et al. Among authors: brecht jg. Pharmacoeconomics. 1998 Dec;14(6):653-69. doi: 10.2165/00019053-199814060-00006. Pharmacoeconomics. 1998. PMID: 10346417

8

Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.

Schädlich PK, Brecht JG, Brunetti M, Pagano E, Rangoonwala B, Huppertz E. Schädlich PK, et al. Among authors: brecht jg. Pharmacoeconomics. 2001;19(5 Pt 1):497-512. doi: 10.2165/00019053-200119050-00005. Pharmacoeconomics. 2001. PMID: 11465309

9

Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective.

Aurbach A, Russ W, Battegay E, Bucher HC, Brecht JG, Schädlich PK, Sendi P. Aurbach A, et al. Among authors: brecht jg. Swiss Med Wkly. 2004 Jul 10;134(27-28):399-405. doi: 10.4414/smw.2004.10498. Swiss Med Wkly. 2004. PMID: 15389357 Free article.

10

Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.

Schädlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG. Schädlich PK, et al. Among authors: brecht jg. Am J Cardiovasc Drugs. 2007;7(3):199-217. doi: 10.2165/00129784-200707030-00006. Am J Cardiovasc Drugs. 2007. PMID: 17610347 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters